STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)



<ul class="wp-block-list">
<li>Code NKI: M15KEY</li>



<li>Code firma: KEYNOTE 158</li>



<li>Code clinicaltrials.gov: NCT02628067</li>
</ul>



Principal Investigator



Dr. M.G.J. van Dongen



Drugs 



Pembrolizumab



<ul class="wp-block-list">
<li>Cohort M: For tumors with TMB-H still &#8211; closed</li>



<li>Cohort K: only for Cohort K-Biliair, Cohort K-Stomach and Cohort K-Thintestine &#8211; open</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).



Read more on <a href="https://www.clinicaltrials.gov/ct2/show/NCT02628067?term=KEYNOTE+158&amp;draw=2&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/ct2/show/NCT02628067?term=KEYNOTE+158&amp;draw=2&amp;rank=1">clinicaltrials.gov</a>.



<h2 class="wp-block-heading">Patient population</h2>



Tumor characteristics: TMB-H (≥10 mut/Mb, F1CDx assay), excluding dMMR/MSI-H tumors